Aravive To Present at The 2020 RBC Capital Markets Global Healthcare Conference
May 12 2020 - 8:00AM
Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical
company developing treatments designed to halt the progression of
life-threatening diseases, including cancer and fibrosis, today
announced that it will present at the 2020 RBC Capital Markets
Virtual Global Healthcare Conference.
Event: 2020 RBC Capital Markets Global Healthcare
ConferencePresentation Date & Time: Tuesday, May 19, 2020 at
10:20 AM ETLocation: Virtual
A live webcast of the presentation will be available at
http://ir.aravive.com.
About AraviveAravive, Inc. (Nasdaq: ARAV) is a
clinical-stage biopharmaceutical company developing treatments
designed to halt the progression of life-threatening diseases,
including cancer and fibrosis. Aravive’s lead product candidate,
AVB-500, is an ultra-high affinity decoy protein that targets the
GAS6-AXL signaling pathway. By capturing serum GAS6, AVB-500
starves the AXL pathway of its signal, potentially halting the
biological programming that promotes disease progression. AXL
receptor signaling plays an important role in multiple types of
malignancies by promoting metastasis, cancer cell survival,
resistance to treatments and immune suppression. The GAS6-AXL
signaling pathway also plays a significant role in fibrogenesis.
Aravive is actively evaluating AVB-500 in platinum-resistant
ovarian cancer and clear cell renal cell carcinoma, and intends to
expand development into additional oncology and fibrotic
indications. Aravive is based in Houston, Texas, and received a
Product Development Award from the Cancer Prevention & Research
Institute of Texas (CPRIT) in 2016. For more information, please
visit www.aravive.com.
Contacts:Investors: Julie SeidelStern Investor
Relationsjulie.seidel@sternir.com
Media: Heidi Chokeir, Ph.D.Canale
Communicationsheidi@canalecomm.com
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Apr 2023 to Apr 2024